Parabilis Medicines, Inc. Common Stock (PBLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Parabilis Medicines, Inc. Common Stock (PBLS) has a cash flow conversion efficiency ratio of -0.003x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.62 Million) by net assets ($1.05 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Parabilis Medicines, Inc. Common Stock market cap and net worth for the company's overall valuation and market capitalisation.
Parabilis Medicines, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Parabilis Medicines, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Parabilis Medicines, Inc. Common Stock stock price for real-time trading data and today's change.
Parabilis Medicines, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Parabilis Medicines, Inc. Common Stock ranked by their cash flow conversion efficiency. Review PBLS financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
H&E Equipment Services Inc
NASDAQ:HEES
|
0.162x |
|
Ninestar Corp
SHE:002180
|
0.017x |
|
Renasant Corporation
NYSE:RNST
|
0.035x |
|
Henan Zhongfu Industrial Co Ltd
SHG:600595
|
0.001x |
|
Inmobiliaria Colonial SA
MC:COL
|
0.006x |
|
Canadian Apartment Properties Real Estate Investment Trust
TO:CAR-UN
|
0.009x |
|
Cosco Shipping Development Co Ltd
SHG:601866
|
0.049x |
|
kakaopay Corp.
KO:377300
|
0.046x |
Annual Cash Flow Conversion Efficiency for Parabilis Medicines, Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Parabilis Medicines, Inc. Common Stock from 2024 to 2025. Also see Parabilis Medicines, Inc. Common Stock assets under control for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-16.52 Million | $-123.71 Million | 7.487x | +507.82% |
| 2024-12-31 | $56.44 Million | $-103.61 Million | -1.836x | -- |
About Parabilis Medicines, Inc. Common Stock
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein … Read more